Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Merck & Co Inc | LSE:0QAH | London | Ordinary Share | MERCK & CO ORD (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 1.80 | 1.80% | 102.00 | 96.80 | 107.20 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 23,929 | 16:35:19 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 60.12B | 365M | 0.1440 | 705.83 | 253.91B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/11/2024 | 19:50 | ALNC |  IN BRIEF: Merck trial shows Koselugo effective in treating adults |
| 31/10/2024 | 11:54 | ALNC | Merck cuts earnings guidance as acquisitions weigh on bottom line |
| 17/9/2024 | 19:15 | ALNC | IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3 |
| 30/7/2024 | 11:59 | ALNC | TOP NEWS: Merck swings to second-quarter profit; trims profit guidance |
| 29/5/2024 | 13:22 | ALNC | Merck & Co enhances ophthalmology portfolio with EyeBio acquisition |
| 25/4/2024 | 11:13 | ALNC | Merck & Co raises annual outlook thanks to first quarter boost |
| 15/3/2024 | 15:23 | ALNC | IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda |
| 20/2/2024 | 21:15 | ALNC | Merck and Astellas drugs get priority review in US and Japan |
| 01/2/2024 | 12:57 | ALNC | TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit |
| 19/1/2024 | 11:29 | ALNC | IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale |
1 Year Merck & Chart |
Intraday Merck & Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
